

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Examiner: To be Assigned
Frederic J. de SAUVAGE, et al.	)	Art Unit: To be Assigned
Application Serial No. To be Assigned	)	Parent Serial No. 09/272,835
Filed: Herewith	)	Parent Filed: March 19, 1999
For: <b>GFR<math>\alpha</math>3 AND ITS USES</b>	)	Attorney's Docket No. 39766-0065 DV1
	)	<b>Customer No. 25213</b>

EXPRESS MAIL LABEL NO. EV 346 723 860 US  
Date Mailed: JULY 16, 2003

**INFORMATION DISCLOSURE STATEMENT**

**Mail Stop Patent Application**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Dear Sir:

Applicants wish to bring to the attention of the Patent Office the references listed on the attached Form PTO-1449 and request that they be considered by the Examiner. Each of the references listed on the attached Form PTO-1449 (**except for the article by Norihiko Nakamura, et al., *The Journal of Biological Chemistry* – 271(32):19483-19488 (1996) is provided**), was previously cited by or submitted to the PTO in prior Application Serial No. 09/272,835, filed **March 19, 1999**, therefore copies are not enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3), therefore no fee is due. The Commissioner is authorized to charge any fees which may be required under 37 CFR §1.16 or §1.17, to Deposit Account No. 08-1641, referencing Attorney's Docket No. 39766-0065 DV1.

Respectfully submitted,

Date: July 16, 2003

By:   
James A. Fox (Reg. No. 38,455)

**HELLER EHRMAN WHITE & McAULIFFE LLP**  
275 Middlefield Road  
Menlo Park, California 94025-3506  
Direct Dial: (650) 324-6951  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
**39766-0065 DV1**Serial No.  
**To be Assigned**

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
**Frederic J. de SAUVAGE, et al.**Filing Date  
**Herewith**Group  
**To be Assigned**

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref No.	Document Number	Date	Name	Class	Subclass	Filing Date
	*1	5,709,858	20.01.98	Godowski et al.	424	143	

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	*2	307,247	15.03.89	EPO				
	*3	846,764	10.06.98	EPO				
	*4	WO 93/06116	01.04.93	PCT				
	*5	WO 97/33912	18.09.97	PCT				
	*6	WO 97/44356	27.11.97	PCT				
	*7	WO 98/53069	26.11.98	PCT				
	*8	WO 98/54213	03.12.98	PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	*9	Arenas et al., "GDNF Prevents Degeneration and Promotes the Phenotype of Brain Noradrenergic Neurons in Vivo" <u>Neuron</u> 15:1465-1473 (1995).					
	*10	Baloh et al., "Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFR $\alpha$ 3-RET receptor complex" <u>Neuron</u> 21(6):1291-1302 (Dec 1998).					
	*11	Beck et al., "Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain" <u>Nature</u> 373:339-341 (1995).					
	*12	Berkemeier et al., "Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB" <u>Neuron</u> 7:857-866 (November 1991).					
	*13	Bollivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" <u>Gene</u> 2:95-113 (1977).					
	*14	Buj-Bello et al., "GDNF Is an Age-Specific Survival Factor for Sensory and Autonomic Neurons" <u>Neuron</u> 15:821-828 (1995).					
	*15	Cash et al., "Parkinson's disease and dementia: Norepinephrine and dopamine in locus ceruleus" <u>Neurology</u> 37:42-46 (1987).					
	*16	Chan-Palay et al., "Alterations in Catecholamine Neurons of the Locus Coeruleus in Senile Dementia of the Alzheimer Type and in Parkinson's Disease With and Without Dementia and Depression" <u>The Journal of Comparative Neurology</u> 287:373-392 (1989).					
	*17	Durbec et al., "GDNF signalling through the Ret receptor tyrosine kinase" <u>Nature</u> 381:789-793 (1996).					
	*18	Hefti, F., "Nerve Growth Factor Promotes Survival of Septal Cholinergic Neurons After Fimbrial Transections" <u>J. of Neuroscience</u> 6(8):2155-2162 (August 1986).					
	*19	Henderson et al., "GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle" <u>Science</u> 266:1062-1064 (1994).					
	*20	Heumann, R., "Regulation of the Synthesis of Nerve Growth Factor" <u>J. Exp. Biol.</u> 132:133-150 (1987).					
	*21	Hirano, A., "Cytopathology of Amyotrophic Lateral Sclerosis" <u>Advances in Neurology: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases</u> , Lewis P. Rowland, Raven Press, Ltd., Chapter 8, Vol. 56:91-101 (1991).					

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

M PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
39766-0065 DV1Serial No.  
To be Assigned

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Frederic J. de SAUVAGE, et al.Filing Date  
HerewithGroup  
To be Assigned

Examiner Initials	Ref. No.	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)
	*22	Hirsch et al., "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease" <u>Nature</u> 334:345-348 (1988),
	*23	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (Sep 13, 1991),
	*24	Hornykiewicz, O., "Neurochemical Pathology and the Etiology of Parkinson's Disease: Basic Facts and Hypothetical Possibilities" <u>Mt. Sinai J. Med.</u> 55:11-20 (1988),
	*25	Jing et al., "GDNF-Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR- $\alpha$ , a Novel Receptor for GDNF" <u>Cell</u> 85:1113-1124 (1996),
	*26	Jing et al., "GFR $\alpha$ -2 and GFR $\alpha$ -3 Are Two New Receptors for Ligands of the GDNF Family" <u>Journal of Biological Chemistry</u> 272(52):33111-33117 (Dec 26, 1997),
	*27	Kaisho et al., "Cloning and expression of a cDNA encoding a novel human neurotrophic factor" <u>FEBS Letters</u> 266(1,2):187-191 (June 1990),
	*28	Kearns et al., "GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo" <u>Brain Research</u> 672:104-111 (1995),
	29	Kotzbauer et al., "Neurturin, a relative of glial-cell-line-derived neurotrophic factor" <u>Nature</u> 384:467-470 (1996),
	*30	Leibrock et al., "Molecular Cloning and Expression of Brain-derived Neurotrophic Factor" <u>Nature</u> 341:149-152 (September 14, 1989),
	*31	Lin et al., "GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons" <u>Science</u> 260:1130-1132 (1993),
	*32	Maisonpierre et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF" <u>Science</u> 247:1446-1451 (March 23, 1990),
	*33	Marcyniuk et al., "The Topography of Cell Loss from Locus Coeruleus in Alzheimer's Disease" <u>J. Neurol. Sci.</u> 76:335-345 (1986),
	*34	Melton et al., "Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter" <u>Nucleic Acids Research</u> 12(18):7035-7056 (Sep 25, 1984),
	*35	Moore et al., "Renal and neuronal abnormalities in mice lacking GDNF" <u>Nature</u> 382:76-79 (1996),
	*36	Oppenheim et al., "Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF" <u>Nature</u> 373:344-346 (1995),
	*37	Phillips et al., "Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons" <u>Science</u> 250(4978):290-294 (Oct. 12, 1990),
	*38	Pichel et al., "Defects in enteric innervation and kidney development in mice lacking GDNF" <u>Nature</u> 382:73-76 (1996),
	*39	Rosenthal et al., "Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor" <u>Neuron</u> 4:767-773 (May 1990),
	*40	Ruppert et al., "Cloning and Expression of Human TAFII250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993),
	*41	Sanchez et al., "Renal agenesis and the absence of enteric neurons in mice lacking GDNF" <u>Nature</u> 382:70-73 (1996),

## EXAMINER:

## DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Atty Docket No. **39766-0065 DV1**

Serial No. \_\_\_\_\_  
To be Assigned \_\_\_\_\_

(Use several sheets if necessary)

Applicant  
**Frederic J. de SAUVAGE, et al.**

Filing Date Herewith	Group To be Assigned
-------------------------	-------------------------

[illegible]

**EXAMINER:**

DATE CONSIDERED:

**EXAMINER:** Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

[illegible]

<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon in a earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	